We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

FDA Approves KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis

News   Feb 01, 2012

 
FDA Approves KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis
 
 
Advertisement
 

RELATED ARTICLES

New Cancer Vaccine Ready for Human Trials

News

A new cancer vaccine, comprised of human antibodies fused with tumor-specific protein, is ready to begin human testing.

READ MORE

Success in Use of Nanoparticles To Deliver Gene Therapy for Eye Disease in Rodents

News

In experiments in rats and mice, scientists report the successful use of nanoparticles to deliver gene therapy for blinding eye disease.

READ MORE

Therapy for Nonalcoholic Fatty Liver Disease Shows Promise in Preclinical Tests

News

Scientists have discovered a new target and a new therapy for Nonalcoholic Fatty Liver Disease (NAFLD), that has shown promising results in preclinical mouse models.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery Genomics Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE